Medidata, a Dassault Systèmes company, has announced that Translational Drug Development (TD2), a precision oncology contract research organization, has signed an agreement to adopt Medidata’s Rave CTMS (Clinical Trial Management System) and eTMF (electronic Trial Master File) solutions, offerings within Medidata’s Unified Platform.
Rave CTMS aims to address struggles that study teams experience in trying to manage and oversee clinical trials due to the fragmented and rapidly changing trial ecosystem. In 2021, Medidata released enhancements to Rave CTMS including ad hoc reporting and proactive risk management support.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.